Kornimate/medical-research-clean huggingface dataset:
randomized study of albuterol in patients with facioscapulohumeral muscular dystrophy

Conditions: Muscular Dystrophy, Facioscapulohumeral

Summary: objectives: i. determine whether albuterol increases strength in patients with facioscapulohumeral dystrophy as measured by quantitative voluntary isometric contraction testing. ii. determine whether albuterol increases muscle mass in this patient population as determined by 24 hour urinary creatinine excretion and dual energy x-ray absorptiometry (dexa). iii. examine the long term safety of albuterol in this patient population.

protocol outline: this is a randomized, double blind, placebo controlled study. patients are randomized into one of three treatment groups. the first group receives placebo. the second group receives low dose albuterol orally every 12 hours. the third group receives high dose albuterol orally every 12 hours. treatment continues for 52 weeks unless unacceptable side effects occur. all patients return for follow up assessments at weeks 4, 12, 24, and 52. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- facioscapulohumeral dystrophy weakness of the facial muscles, including frontalis, orbicularis oculi, or orbicularis oris weakness of scapular stabilizers or foot dorsiflexors weakness of grade 2 or worse in the arm using the upper extremity grading scale no other neuromuscular diseases that may mimic the clinical presentation of facioscapulohumeral dystrophy: ptosis or ophthalmoparesis (other than congenital strabismus) elbow contractures strictly unilateral weakness dermatomyositis-like skin rash symmetric distal sensory loss muscle biopsy findings of mitochondrial myopathy, chronic denervation, dermatomyositis, inclusion body myositis, or congenital myopathy electromyographic (emg) findings of myotonia, fasciculations, or neurogenic motor unit potentials --prior/concurrent therapy-- endocrine therapy: no prior long term use of oral corticosteroids for more than 1 year at least 3 months since prior use of corticosteroids no concurrent use of immunosuppressive agents surgery: no concurrent surgeries other: no concurrent use of sympathomimetic agents, antidepressants, or beta receptor blockers --patient characteristics-- age: 18 to 80 performance status: ambulatory cardiovascular: no cardiovascular disease, including hypertension and coronary artery disease other: not pregnant or nursing no concurrent uncontrolled medical or psychological condition

Keywords: genetic diseases and dysmorphic syndromes muscular dystrophy neurologic and psychiatric disorders rare disease
a cohort of predictive factor of pathologic complete response after preoperative neoadjuvant in rectum cancer

Conditions: Rectum Cancer

Summary: due to colorectal cancer is the fourth most common malignancy in the world. some patients had present locally advance stage and need to preoperative concurrent chemoradiation (ccrt) before radical surgery. but predictor for pathologic complete response (pcr) after preoperative ccrt remain unclear. objectives: to identify possible factor for predict of pcr of rectal cancer after preoperative ccrt.

after permission was obtained from our institutional review board, a cohort of patients who were diagnosed with rectal cancer and received chemoradiation between january 2011 to december 2017 at ramathibodi hospital, bangkok were analyzed. patients who were not received neoadjuvant chemoradiation therapy, loss follow-up, incomplete data in the record, distant organ metastasis and who was not received colorectal surgery were excluded as study flow diagram. age, sex, performance status, smoking, initial hb level (g/ml), cea level (ng/dl), distance of tumor from anal verge, diagnostic variables, clinical t staging, preoperative thickness and length from computer tomography scan (ct scan), organ metastasis before treatment, histology, treatment course, and outcomes after treatment were collected and analyzed.total dose of radiation, interval time from ccrt to operation, and chemotherapy regimens were also collected between and after treatment. after preoperative ccrt, the radical rectal surgery was performed by eight experienced general surgeons and surgical oncologist using open and laparoscopic techniques. perioperative data were collected and histology was evaluated by an experienced pathologists. for pathological classification, pathological responses were divided in 2 groups i.e., pathologic complete response (pcr group) and non-pcr group, (partial response, stable disease, and disease progression). margin of lesions were classified as proximal, distal and circumferential margins. lymph nodes status after surgery were specified as total lymph nodes harvested and positive lymph nodes.

Eligibility criteria:
inclusion criteria: * rectal cancer and received preoperative chemoradiation exclusion criteria: * distant organ metastasis * previous colorectal surgery

Keywords: preoperative chemoradiation rectum cancer pathological complete response
study evaluating inhibitor specificity in hemophilia a

Conditions: Hemophilia A

Summary: this investigation will utilize a systematic determination of anti-fviii antibody specificity in ptps (\> 50 ed) with hemophilia a who have developed inhibitors in response to treatment with any fviii product(s). a group of patients with hemophilia a, who have no evidence of current or prior fviii inhibitor will be included for comparison. the objective of this study is to describe the patterns of antibodies and associated epitopes in the study population.


Eligibility criteria:
inclusion criteria: · patients with moderate or severe congenital hemophilia a, a current fviii inhibitor, who have taken at least two different fviii products during their lifetime. exclusion criteria: * patients who have had an inhibitor prior to their current inhibitor. * patients with immune disorders.
fnirs, listening effort, and speech intelligibility

Conditions: Hearing Loss

Summary: the purpose of the current study is to measure oxygenation in the pfc using fnirs in a sample of older adults with hearing loss. adults with hearing loss will be asked to repeat the final word from low-context sentences in noise at two snrs; a hard snr (individually-measured snr-50), and an easy snr (snr-50 + 10 db) both without and with hearing aids set to a directional mode. the procedure will be a within-subject repeated measures. stimuli will be randomized.

see above.

Eligibility criteria:
inclusion criteria: * adults (18-99 years) with ≥3 months hearing aid experience * binaural, symmetric, sensorineural n2 (mild) to n6 (severe) hearing loss * fluent in english exclusion criteria: * children/teenagers * normal hearing or hearing loss exceeding n6 (severe) by 10 db
mini distractor in vertically deficient bone

Conditions: Periodontitis; Alveolar Bone Loss

Summary: ado is a bone regeneration technique, introduced by chin and toth in 1996 based in a biological process used for regenerate and consolidate bone between two bone segments obtained after osteotomy.these segments have been gradually separated by the process of distraction. ado can be performed both horizontally (ahdo) and vertically (avdo).

distraction osteogenesis (do) can be used to regenerate missing hard and soft tissue, distraction osteogenesis relies on the body's ability to generate bone as two segments of bone are "distracted" apart. the osteotomies are created and the distraction device is placed. typically, there is a latency phase of one week were a ﬁbrovascular bridge is formed in the osteotomy site. this provides a template to generate new bone as the segments are distracted apart during the activation phase. once the desired distraction has occurred, the device is left in place for a period of time. once consolidation (typically 2 to 6 months) has occurred, the distraction device can be removed and implants can be placed. chiapasco compared gbr to do and found that both are equally effective in alveolar bone augmentation for implant placement and further stated that the long-term prognosis of vertical bone gain in do is more predictable.

Eligibility criteria:
inclusion criteria: * acquired alveolar defects (post extraction, traumatic avulsion of teeth, periodontal disease, after tumor resection), congenital alveolar defects, vertically deficient edentulous ridge in maxillary or mandibular anterior region with * allen type a moderate vertical ridge deficiency (3-6mm) exclusion criteria * medically compromised patients * subjects who underwent radiotherapy or chemotherapy * smokers and * radiographic presence of less than 5mm of anterior maxillary and mandibular bone height
a dose-escalation study designed to evaluate the tolerability, safety, pharmacokinetics (pk), and efficacy of chronic topical ocular application of ino-8875 in adults with ocular hypertension or primary open-angle glaucoma

Conditions: Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to evaluate how tolerable, safe, and effective it is to give ino-8875 eye drops to adults with glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: 1. subject has the diagnosis of ocular hypertension (oht) or primary open-angle glaucoma (poag). 2. aged 18 to 75 years. 3. mean intraocular pressure (iop) of ≥24 and ≤34 mm hg. exclusion criteria: 1. no significant visual field loss or any new field loss within the past year. 2. cup-to-disc ratio ≥0.8 3. central corneal thickness \ 600 µm 4. history of adult asthma or chronic obstructive pulmonary disease 5. a recent (acute) or chronic medical condition that might obfuscate the subject's study data

Keywords: glaucoma ocular hypertension adenosine agonist eye drop primary open angle glaucoma
effect psychological triaging intervention on students' psychological distress and resilience capacity

Conditions: Psychological Distress; Resilience

Summary: this study aimed to investigate the effect of the psychological triaging intervention (pti) on the psychological distress and resilience capacity levels among the intern-nursing students during the covid-19 crisis. research hypothesis intern-nursing students who attend pti exhibit lower covid-19 related psychological distress level and higher resilience capacity than those who receive routine psychological support.

the intern-nursing students' psychological well-being and resilience are of indispensable significance during these unprecedented days. 64 intern-nursing students. sixty-four intern-nursing students who completed a preliminary survey and demonstrated both high level of psychological distress and low resilience capacity as a result of their exposure to patients with covid-19 during their internship period were randomly assigned to two equal groups and the study group were engaged in the pti intervention which followed the path of rapid psychological first aid model. the pti intervention followed the path of rapid psychological first aid model of john hopkins university (everly\& lating 2012). the content of the pti represents a simple structure that is revolved around five core phases including (r: establishing rapport and reflective listening, a: assessment, p: prioritization, i: intervention and d: disposition\& follow up).

Eligibility criteria:
inclusion criteria: * exposed to patients with covid-19 exclusion criteria: * did not exposed to patients with covid-19

Keywords: psychological distress triage resilience covid-19
oxytocin and eating

Conditions: Weight Gain

Summary: in this protocol, the investigators propose a randomised controlled trial to explore the effects of intra-nasal oxytocin administration on appetite regulation. the investigators will run a cross-over design with 60 healthy adult men.


Eligibility criteria:
inclusion criteria: * gender: male * age: 21-45 years * normal weight: body mass index of 18.5 to 22.9 * have had a stable weight for the past 3 months (less than 5kg) * have regular breakfast meals (≥ 4 times a week of self-reported consumption of a breakfast meal) * have habitual sleep of 6.5-8.5 hours * have english as first language (or fluent in spoken and written english) exclusion criteria: * symptoms / history of any major medical condition, including: * bariatric surgery or surgical obesity treatment * diabetes * cardiovascular disease * thyroid disease * anaemia * psychiatric disorders * eating disorders * excessive exercise (running \> 40 km or exercising \> 10 hr in a week) * currently on a special diet or trying deliberately to restrict food intake * currently on a weight loss program * smoking or substance abuse * use of medications that can affect weight (e.g., steroids, approved weight-loss drugs)

Keywords: appetite regulation obesity oxytocin
the effect of virtual reality-based disaster education given to nursing students on disaster preparedness

Conditions: Disaster; Personality; Disorder, Mood

Summary: it is thought that, as a result of the virtual reality-based disaster training given to nursing students, the psychological preparedness of nursing students who will work before, during and after the disaster will increase in disaster preparedness and disaster threat. it is thought that this research will lead to the development of school-based interventions at other universities in similar situations. the purpose of this research is to increase the level of psychological preparation and awareness of disaster preparedness and disaster threat through virtual reality-based disaster education given to nursing students.


Eligibility criteria:
inclusion criteria: * being a 3rd and 4th year nursing student at the relevant universities where the study will be conducted, * not having taken the disaster management course before, * not having any health problems related to vision and hearing, * not wearing glasses to be able to use virtual reality (vr) glasses exclusion criteria: * having any problems with vision or hearing * using glasses

Keywords: disaster disaster preparedness psychological preparedness nursing students virtual reality
high-density mapping-guided box isolation and substrate ablation

Conditions: Atrial Fibrillation; Atrial Remodeling

Summary: this study evaluates the efficacy of high-density mapping guided atrial substrate ablation for persistent atrial fibrillation. 1/5 of the patients with persistent atrial fibrillation undergo pulmonary veins isolation, 2/5 of them pulmonary veins and box isolation while others undergo atrial substrate ablation apart from pulmonary veins and box isolation.


Eligibility criteria:
inclusion criteria: * informed consent signed. * age of 18 to 75 years old. * persistent or longstanding persistent atrial fibrillation (≥7 days), which is confirmed by holter in recent six months. * willing to have catheter ablation for atrial fibrillation. exclusion criteria: * accompanied by serious heart diseases including cardiac valvular diseases, congenital heart diseases, hypertrophic obstructive cardiomyopathy, acute myocardium infarction, unstable anginal pectoris and so on. * complete atrioventricular block. * an acute stroke or contradiction of anti-coagulation. * hyperthyroidism. * having a history of catheter ablation of atrial fibrillation. * left atrial appendage thrombosis confirmed by transesophageal echocardiography. * pregnancy or lactation. * planning for pregnancy in the near future. * myopathy or active liver disease, including patients with sustained increase of serum transaminase of unknown reason and the ones with increased serum transaminase over three times the upper limit of normal. * patients of severe renal insufficiency with creatinine clearance lower than 30 ml/min.

Keywords: catheter ablation
comparison of a two ready-to-use supplementary foods of differing protein quality for the treatment of mam.

Conditions: Malnutrition

Summary: this is a prospective, randomised, double-blinded, controlled clinical effectiveness trial of two supplementary foods in the treatment of mam. the setting will be 21 rural sites in southern malawi. the participants will be 1800 children 6-59 months old with mam, defined as mid-upper arm circumference (muac) ≥ 11.5 cm and \ -2 by 12 weeks) or failure (death, development of severe acute malnutrition, transfer to hospital for inpatient care, failure to recover from mam by 12 weeks, default). secondary outcome measures include rates of weight, height, and mid-upper-arm circumference (muac) gain, time to graduation, and adverse effects from the supplementary foods.


Eligibility criteria:
inclusion criteria: * muac \< 12.5 cm and ≥ 11.5 cm * without bipedal edema exclusion criteria: * simultaneously involved in another research trial or supplemental feeding program * developmentally delayed, have a chronic debilitating illness such as cerebral palsy * history of peanut or milk allergy

Keywords: moderate acute malnutrition, malnutrition
tacs treatment for cognitive impairments in methamphetamine addicts

Conditions: Methamphetamine Abuse

Summary: 1. to evaluate the cognitive function of methamphetamine patients. 2. investigate the pathological mechanism of methamphetamine patients from the aspects of eeg and biology; 3. the investigators investigated the effects of transcranial alternating current stimulation (tacs) on cognitive impairments in methamphetamine patients


Eligibility criteria:
inclusion criteria: * clinical diagnosis diagnosis of methamphetamine use disorder according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) * none of participants had mixed use of other drugs * none of participants had physical disability * none of participants had acute physical or mental illness, hallucinations, acute withdrawal symptoms * none of participants were receiving any medical treatment exclusion criteria: * intracranial hypertension * cranial defects * tumors * serious physical illnesses (e.g., cardiovascular, liver, kidney, gastrointestinal disorders) * infectious diseases * immune system disorders

Keywords: methamphetamine patients cognitive impairments tacs
a study to evaluate the efficacy and safety of mk-1167 in participants with alzheimer's disease dementia (mk-1167-008)

Conditions: Alzheimer Disease; Dementia

Summary: researchers want to learn if giving mk-1167 (the study medicine) along with acetylcholinesterase inhibitor (achei) therapy can improve symptoms of alzheimer's disease dementia (ad dementia), such as memory and mental activity. ad dementia is the most common type of dementia. achei therapy is the standard treatment for ad dementia. the goals of this study are to learn: * if at least one dose level (amount) of mk-1167 works to improve a person's memory and thinking compared to a placebo * about the safety of mk-1167 and if people tolerate it


Eligibility criteria:
inclusion criteria: * has mild to moderate alzheimer's disease (ad) dementia (ie, stage 4 or stage 5 ad) based on the alzheimer's association revised criteria for diagnosis and staging of alzheimer's disease * has a mini-mental state examination (mmse) score of 12 to 24 (inclusive) * is using acetylcholinesterase inhibitors (achei) therapy for management of ad dementia * has a designated study partner who can fulfill the requirements of this study. the study partner will need to spend sufficient time with the participant to be familiar with their overall function and behavior and be able to provide adequate information about the participant needed for the study including, knowledge of functional and basic activities of daily life, work/educational history, cognitive performance, emotional/psychological state, and general health status exclusion criteria: * has a known history of stroke or cerebrovascular disease * has diagnosis of a clinically relevant central nervous system (cns) disease other than ad dementia or other condition that negatively impacts cognition or cognitive status chronically * has structural brain disease * has a history of seizures or epilepsy * has any other major cns trauma, or infections that affect brain function (eg, human immunodeficiency virus (hiv), syphilis, and/or neurological sequelae of coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (covid-19), including impact on cognition) * has major medical illness or unstable medical condition * has a history of malignancy * resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision (with protocol-specified exceptions) * has liver disease, including but not limited to chronic viral hepatitis, nonviral hepatitis, cirrhosis, malignancies, autoimmune liver diseases
noroxin efficacy and safety trial

Conditions: Urinary Tract Infections

Summary: to determine the efficacy and safety of norfloxacin (noroxin)

urinary tract infections (utis) are some of the most common bacterial infections, affecting 150 million people each year worldwide. clinically, utis are categorized as uncomplicated or complicated. uncomplicated utis typically affect individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities; these infections are differentiated into lower utis (cystitis) and upper utis (pyelonephritis). several risk factors are associated with cystitis, including female gender, a prior uti, sexual activity, vaginal infection, diabetes, obesity and genetic susceptibility. utis are caused by both gram-negative and gram-positive bacteria, as well as by certain fungi. the most common causative agent for both uncomplicated and complicated utis is uropathogenic escherichia coli (upec). for the agents involved in uncomplicated utis, upec is followed in prevalence by klebsiella pneumoniae, staphylococcus saprophyticus, enterococcus faecalis, group b streptococcus (gbs), proteus mirabilis, pseudomonas aeruginosa, staphylococcus aureus and candida spp. currently, antibiotics - such as trimethoprim sulfamethoxazole, floxacin and ampicillin - are the most commonly recommended therapeutics for utis6. utis are becoming increasingly difficult to treat owing to the widespread emergence of an array of antibiotic resistance mechanisms. of particular concern are members of the family enterobacteriaceae, including e. coli and k. pneumoniae, which have both acquired plasmids encoding extended-spectrum β-lactamases (esbls). these plasmids rapidly spread resistance to third-generation cephalosporins as well as other antibiotics.

Eligibility criteria:
inclusion criteria: * written informed consent * at least one typical symptom of acute, lower urinary tract infection out of dysuria, frequency, macrohaematuria, cloudy or smelly urine or self-diagnosed cystitis exclusion criteria: * duration of uti symptoms for more than 7 days before physician's visit * clinical signs of invasiveness such as fever (axillary body temperature \>38 degrees celsius), costovertebral pain or tenderness, rigors, nausea or vomiting * known or suspicion of anatomical or functional abnormality of the urinary tract * vaginal symptoms: discharge, irritation * diabetes mellitus * immunosuppression (e.g. prednisone equivalent \>10mg per day for \>14 days, chemotherapy, radiotherapy, immunomodulators, hiv infection, neutropenia) * any other serious comorbidity as judged by the treating physician * bladder catheter in situ or during the past 30 days * pregnancy * recurrent urinary tract infection (more than 3 infections during the last 12 months) * antibiotic treatment during the last 4 weeks

Keywords: urinary tract infection norfloxacin fluroquinolone safety pakistan